CEO Leslie Trigg was paid $3,255,510 in fiscal year 2025, ↓ down 18.7% from fiscal year 2024, the 25th percentile of its disclosed peer group (SEC filing 0001193125-26-177150 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,398,025 Renee Gaeta total, FY2025 Chief Financial Officer — highest-paid officer; CEO Leslie Trigg: $3,255,510 | 25th CEO (Leslie Trigg) pay percentile vs peers | 24:1 CEO-to-median pay ratio | 70.25% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
OM's next annual pay disclosure, estimated May 7, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Renee Gaeta | $276,923 | $0 | $3,061,977 | $0 | $54,000 | $0 | $5,125 | $3,398,025 |
| Chief Financial Officer | ||||||||
| Leslie Trigg | 755,166 | 0 | 2,197,882 | 0 | 294,515 | 0 | 7,947 | 3,255,510 |
| President, CEO and Chair of the Board | ||||||||
| John Brottem | 466,595 | 1,000 | 838,557 | 0 | 90,986 | 0 | 7,506 | 1,404,644 |
| General Counsel and Secretary | ||||||||
| Marc Nash | 432,577 | 0 | 783,340 | 0 | 84,353 | 0 | 7,198 | 1,307,468 |
| Executive Vice President, R&D, Operations and Service | ||||||||
| Nabeel Ahmed | 212,841 | 0 | 0 | 0 | 0 | 0 | 397,287 | 610,128 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Renee Gaeta | $3,398,025 | — | — | — |
| Leslie Trigg | 3,255,510 | 4,002,620 | 6,474,946 | ↓ −747,110 |
| John Brottem | 1,404,644 | 1,510,518 | 1,744,514 | ↓ −105,874 |
| Marc Nash | 1,307,468 | — | — | — |
| Nabeel Ahmed | 610,128 | 1,791,014 | 2,328,951 | ↓ −1,180,886 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Outset Medical's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper OM reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses OM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Renee Gaeta | CFO | $3,398,025 |
| Leslie Trigg | CEO | $3,255,510 |
| Marc Nash | EVP | $1,307,468 |
| Nabeel Ahmed | CFO | $610,128 |
| John Brottem | General Counsel | $1,404,644 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Andrea L. Saia | Former director (through FY2025) | $214,987 |
| Brent D. Lang | Independent Director | $214,987 |
| D. Keith Grossman | Lead Independent Director | $271,278 |
| Dale E. Jones | Former director (through FY2025) | $24,107 |
| Karen Drexler | Independent Director | $224,987 |
| Karen Prange | Independent Director | — |
| Kevin O'Boyle | Independent Director | $480,878 |
| Patrick T. Hackett | Independent Director | $223,696 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Braden Michael Leonard | Greater-than-10% holder | 2026-05-08 | A | 197,600 | $5 | $988,000 | Common, indirect | Form 4 ↗ |
| Braden Michael Leonard | Greater-than-10% holder | 2026-05-11 | A | 96,900 | 5 | 484,500 | Common, indirect | Form 4 ↗ |
| John Brottem | General Counsel | 2026-05-15 | D | 2,638 | 4 | 9,761 | Common | Form 4 ↗ |
| Marc Nash | EVP Operations R&D & Service | 2026-05-15 | D | 1,582 | 4 | 5,853 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-05-15 | D | 3,445 | 4 | 12,747 | Common | Form 4 ↗ |
| Braden Michael Leonard | Greater-than-10% holder | 2026-05-15 | A | 323,000 | 5 | 1,615,000 | Common, indirect | Form 4 ↗ |
| Renee Gaeta | Chief Financial Officer | 2026-06-03 | D | 17,672 | 5 | 87,300 | Common | Form 4 ↗ |
| Karen Drexler | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| D. Keith Grossman | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Karen Prange | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Kevin C. Oboyle | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Patrick T. Hackett | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Brent D. Lang | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Renee Gaeta | Chief Financial Officer | 2026-06-26 | A | 71,630 | 0 | 0 | Common | Form 4 ↗ |
| John Brottem | General Counsel | 2026-06-26 | A | 59,830 | 0 | 0 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-06-26 | A | 99,160 | 0 | 0 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-08-17 | D | 3,437 | 4 | 15,088 | Common | Form 4 ↗ |
| Renee Gaeta | Chief Financial Officer | 2026-08-17 | D | 4,543 | 4 | 19,944 | Common | Form 4 ↗ |
| John Brottem | General Counsel | 2026-08-17 | D | 2,632 | 4 | 11,554 | Common | Form 4 ↗ |
| Braden Michael Leonard | Greater-than-10% holder | 2026-10-01 | A | 228,334 | 4 | 806,019 | Common, indirect | Form 4 ↗ |
| Braden Michael Leonard | Greater-than-10% holder | 2026-10-02 | A | 16,575 | 4 | 64,241 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Brottem | PSU | 2025-06-10 | 1,349 | 2,699 | — | 5,398 | $95,302 |
| John Brottem | RSU | 2025-06-10 | — | — | 35,993 | — | 743,255 |
| Leslie Trigg | RSU | 2025-06-10 | — | — | 65,103 | — | 1,344,377 |
| Renee Gaeta | PSU | 2025-06-10 | 4,928 | 9,857 | — | 19,714 | 348,051 |
| Renee Gaeta | RSU | 2025-06-10 | — | — | 131,425 | — | 2,713,926 |
| Marc Nash | PSU | 2025-06-10 | 1,113 | 2,226 | — | 4,452 | 78,600 |
| Marc Nash | RSU | 2025-06-10 | — | — | 29,676 | — | 612,809 |
| Marc Nash | RSU | 2025-08-25 | — | — | 5,617 | — | 77,065 |
| Leslie Trigg | PSU | 2025-06-10 | 9,765 | 19,531 | — | 48,827 | 853,505 |
| Marc Nash | PSU | 2025-08-25 | 210 | 421 | — | 842 | 14,866 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Brottem | $743,255 | $95,302 | $0 | 11.4% |
| Leslie Trigg | 1,344,377 | 853,505 | 0 | 38.8% |
| Renee Gaeta | 2,713,926 | 348,051 | 0 | 11.4% |
| Marc Nash | 689,874 | 93,466 | 0 | 11.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Marc Nash | RSU | 2,135 | — | $7,921 |
| Marc Nash | RSU | 29,676 | — | 110,098 |
| John Brottem | PSU | 1,349 | — | 5,005 |
| John Brottem | PSU | 240 | — | 890 |
| Marc Nash | RSU | 8,609 | — | 31,939 |
| Leslie Trigg | RSU | 24,177 | — | 89,697 |
| John Brottem | PSU | 1,666 | — | 6,181 |
| Marc Nash | PSU | 240 | — | 890 |
| Marc Nash | PSU | 210 | — | 779 |
| Leslie Trigg | RSU | 4,724 | — | 17,526 |
| Marc Nash | PSU | 1,666 | — | 6,181 |
| Leslie Trigg | PSU | 9,765 | — | 36,228 |
| Nabeel Ahmed | RSU | 9,315 | — | 34,559 |
| Leslie Trigg | PSU | 2,125 | — | 7,884 |
| Marc Nash | RSU | 107 | — | 397 |
| John Brottem | RSU | 35,993 | — | 133,534 |
| Renee Gaeta | RSU | 131,425 | — | 487,587 |
| Marc Nash | PSU | 1,113 | — | 4,129 |
| Leslie Trigg | RSU | 65,103 | — | 241,532 |
| Renee Gaeta | PSU | 4,928 | — | 18,283 |
| John Brottem | RSU | 9,061 | — | 33,617 |
| Marc Nash | RSU | 5,617 | — | 20,839 |
| Leslie Trigg | PSU | 3,333 | — | 12,365 |
| Leslie Trigg | PSU | 1,942 | — | 7,205 |
| John Brottem | RSU | 2,135 | — | 7,921 |
Our executive compensation program is designed to meet the following key objectives: Attract, mobilize and retain the right talent. Executive compensation should be market-competitive in order to attract and retain highly qualified, experienced and motivated talent to act as inspirational leaders, drive our strategic initiatives, grow our business and help pave the way to a patient-centric dialysis service model. Incentivize a collective focus on corporate goals. Our work environment is goal-driven and we believe compensation is a critical tool in the successful execution of our business objectives. By tying elements of our executives pay to key corporate goals, we encourage our executives to focus their teams and execute on these goals. Reward and recognize outstanding performance. We firmly believe that executive compensation should incentivize and reward outstanding performance that contributes to our overall growth and success as a company both in the short term and long term. Create long-term stockholder value. Through the risks and rewards of owning Outset equity, we incentivize our executives to stay focused collectively on activities that intended to ensure Outset s sustainable success.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 7,548,774 | 3,196,870 | 6,411 | 70.25% | Passed |
| 2025 | 2025-06-02 | 13,574,133 | 342,501 | 5,839 | 97.54% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-04 | 70.25%a |
| 2025 | 2025-06-02 | 97.54%b |
a. Approved under the standard stated in the filing — “Abstentions are not considered "votes cast" and therefore will not affect the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions are not considered "votes cast" and therefore will not affect the outcome of this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 24 : 1 |
|---|---|
| CEO total compensation | $3,255,510 |
| Median employee compensation | $135,629 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kevin O'BoyleIndependent · Newly elected | $40,893 | $439,985 | $0 | $0 | $0 | $480,878 |
| D. Keith GrossmanIndependent · Lead Independent Director · Compensation (Chair) · Nominating and Corporate Governance | 111,291 | 159,987 | 0 | 0 | 0 | 271,278 |
| Karen DrexlerIndependent · Compensation · Nominating and Corporate Governance (Chair) | 65,000 | 159,987 | 0 | 0 | 0 | 224,987 |
| Patrick T. HackettIndependent · Audit · Nominating and Corporate Governance | 63,709 | 159,987 | 0 | 0 | 0 | 223,696 |
| Andrea L. SaiaIndependent · Audit · Compensation · Departed during FY | 55,000 | 159,987 | 0 | 0 | 0 | 214,987 |
| Brent D. LangIndependent · Audit | 55,000 | 159,987 | 0 | 0 | 0 | 214,987 |
| Dale E. JonesIndependent · Compensation (Chair) · Departed during FY | 24,107 | — | 0 | 0 | 0 | 24,107 |
| Karen PrangeIndependent · Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Leslie TriggEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $160,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $415,000 |
| Equity awards (grant-date value) | $1,239,920 |
| All other compensation | $0 |
| Total cost of the board | $1,654,920 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Outset Medical names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Outset Medical.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PROCEPT BioRobotics Corporation | 2025 | Larry Wood | $304,830 | $7,217,251 | $7,226,599 | $243,864 | $16,783,853 |
| 2 | Nevro Corp. | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 3 | Adaptive Biotechnologies Corporation | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 4 | SI-BONE, Inc. | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 5 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 6 | Butterfly Network, Inc. | 2025 | Joseph DeVivo | 900,300 | 4,291,604 | 0 | 1,183,000 | 6,382,814 |
| 7 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 8 | Treace Medical Concepts, Inc. | 2025 | John Treace | 755,353 | 4,635,000 | 0 | 0 | 5,405,190 |
| 9 | Accuray Incorporated | 2026 | Steve La Neve | 525,000 | 4,263,749 | 0 | 0 | 5,114,466 |
| 10 | Neuronetics, Inc. | 2025 | Keith Sullivan | 728,000 | 3,208,750 | 0 | 412,776 | 4,365,064 |
| 11 | Pacific Biosciences of California, Inc. | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 12 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 13 | Outset Medical | 2025 | Leslie Trigg | 755,166 | 2,197,882 | 0 | 294,515 | 3,255,510 |
| 14 | Paragon 28, Inc. | 2023 | Albert DaCosta | 700,769 | 1,832,495 | 0 | 667,400 | 3,232,420 |
| 15 | Inogen, Inc. | 2025 | Kevin R.M. Smith | 711,077 | 1,874,550 | 0 | 0 | 2,613,804 |
| 16 | NeuroPace, Inc. | 2025 | Joel Becker | 567,567 | 587,340 | 701,850 | 551,810 | 2,408,566 |
| 17 | Sight Sciences, Inc. | 2025 | Paul Badawi | 659,000 | 1,000,000 | 0 | 334,607 | 2,005,608 |
| — | Pulmonx Corporation | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Outset Medical | 39% | PSU 50 · RSU 50 | Yes — Relative TSR compared to Russell 2000 Medical Device Index | Pearl Meyer |
| Accuray Incorporated | 0% | PSU 50 · RSU 50 | No | Exequity LLP |
| Adaptive Biotechnologies Corporation | not disclosed | RSU 50 · PSU 50 | not disclosed | Semler Brossy Consulting Group, LLC |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Butterfly Network, Inc. | 131.25% for Joseph DeVivo; 109.2% for Steven Cashman% | not disclosed | No | Pay Governance |
| CareDx, Inc. | 122% | RSU 70 · PSU 30 | No | Alpine Rewards |
| Inogen, Inc. | 60% | RSU 50 · PRSU 50 | No | Aon |
| Neuronetics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| NeuroPace, Inc. | not disclosed | not disclosed | not disclosed | Alpine, Inc. |
| Nevro Corp. | 53.7% | not disclosed | No | Aon |
| Pacific Biosciences of California, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Paragon 28, Inc. | 94% | RSU 100 | not disclosed | Compensia, Inc. |
| PROCEPT BioRobotics Corporation | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| Pulmonx Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| SI-BONE, Inc. | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| Sight Sciences, Inc. | not disclosed | RSU 100 | not disclosed | Compensia, Inc. |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Treace Medical Concepts, Inc. | not disclosed | RSU 50 · PSU 50 | No | Compensia, Inc. |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Renee Gaeta | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “2025 Summary Compensation Table”. As printed: 3,398,025. Filing ↗machine: r5 · c30 · span 1380413–1380422 |
| 2 | Section 01, Leslie Trigg | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “2025 Summary Compensation Table”. As printed: 3,255,510. Filing ↗machine: r2 · c30 · span 1343364–1343373 |
| 3 | Section 01, John Brottem | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “2025 Summary Compensation Table”. As printed: 1,404,644. Filing ↗machine: r8 · c30 · span 1417411–1417420 |
| 4 | Section 01, Marc Nash | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “2025 Summary Compensation Table”. As printed: 1,307,468. Filing ↗machine: r11 · c30 · span 1454382–1454391 |
| 5 | Section 01, Nabeel Ahmed | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “2025 Summary Compensation Table”. As printed: 610,128. Filing ↗machine: r14 · c30 · span 1491360–1491367 |
| 6 | Section 03, John Brottem PSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r5 · c15 · span 1279868–1279873 |
| 7 | Section 03, John Brottem RSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r5 · c7 · span 1276940–1276946 |
| 8 | Section 03, Leslie Trigg RSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r3 · c7 · span 1252391–1252397 |
| 9 | Section 03, Renee Gaeta PSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r4 · c31 · span 1273458–1273463 |
| 10 | Section 03, Renee Gaeta RSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r4 · c23 · span 1270531–1270538 |
| 11 | Section 03, Marc Nash PSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r6 · c15 · span 1292137–1292142 |
| 12 | Section 03, Marc Nash RSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r6 · c7 · span 1289209–1289215 |
| 13 | Section 03, Marc Nash RSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r6 · c23 · span 1295078–1295083 |
| 14 | Section 03, Leslie Trigg PSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r3 · c15 · span 1255320–1255326 |
| 15 | Section 03, Marc Nash PSU | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t95 · r6 · c31 · span 1298000–1298003 |
| 16 | Section 07, pay ratio | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “CEO Pay Ratio”. As printed: 24 : 1. Filing ↗ |
| 17 | Section 08, Kevin O'Boyle | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 480,878. Filing ↗machine: t58 · r7 · c15 · span 757181–757415 |
| 18 | Section 08, D. Keith Grossman | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 271,278. Filing ↗machine: t58 · r3 · c15 · span 730995–731229 |
| 19 | Section 08, Karen Drexler | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 224,987. Filing ↗machine: t58 · r2 · c15 · span 724541–724775 |
| 20 | Section 08, Patrick T. Hackett | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 223,696. Filing ↗machine: t58 · r4 · c15 · span 737449–737683 |
| 21 | Section 08, Andrea L. Saia | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 214,987. Filing ↗machine: t58 · r8 · c15 · span 763824–764058 |
| 22 | Section 08, Brent D. Lang | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 214,987. Filing ↗machine: t58 · r6 · c15 · span 750539–750773 |
| 23 | Section 08, Dale E. Jones | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 24,107. Filing ↗machine: t58 · r5 · c3 · span 739652–739885 |
| 24 | Section 08, Karen Prange | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 25 | Section 08, Leslie Trigg | DEF 14A | 2026-04-24 | 0001193125-26-177150 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 26 | Section 02, Braden Michael Leonard 2026-05-08 | Form 4 | 2026-05-12 | 0001373604-26-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Braden Michael Leonard 2026-05-11 | Form 4 | 2026-05-12 | 0001373604-26-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, John Brottem 2026-05-15 | Form 4 | 2026-05-19 | 0001484612-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Marc Nash 2026-05-15 | Form 4 | 2026-05-19 | 0001484612-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Leslie Trigg 2026-05-15 | Form 4 | 2026-05-19 | 0001484612-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Braden Michael Leonard 2026-05-15 | Form 4 | 2026-05-18 | 0001373604-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Renee Gaeta 2026-06-03 | Form 4 | 2026-06-05 | 0001484612-26-000029 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Karen Drexler 2026-06-04 | Form 4 | 2026-06-05 | 0001484612-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, D. Keith Grossman 2026-06-04 | Form 4 | 2026-06-05 | 0001484612-26-000031 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Karen Prange 2026-06-04 | Form 4 | 2026-06-05 | 0001484612-26-000034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Kevin C. Oboyle 2026-06-04 | Form 4 | 2026-06-05 | 0001484612-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Patrick T. Hackett 2026-06-04 | Form 4 | 2026-06-05 | 0001484612-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Brent D. Lang 2026-06-04 | Form 4 | 2026-06-05 | 0001484612-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Renee Gaeta 2026-06-26 | Form 4 | 2026-06-29 | 0001484612-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, John Brottem 2026-06-26 | Form 4 | 2026-06-29 | 0001484612-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Leslie Trigg 2026-06-26 | Form 4 | 2026-06-29 | 0001484612-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Leslie Trigg 2026-08-17 | Form 4 | 2026-08-18 | 0001484612-26-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Renee Gaeta 2026-08-17 | Form 4 | 2026-08-18 | 0001484612-26-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, John Brottem 2026-08-17 | Form 4 | 2026-08-18 | 0001484612-26-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Braden Michael Leonard 2026-10-01 | Form 4 | 2026-10-05 | 0001373604-26-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Braden Michael Leonard 2026-10-02 | Form 4 | 2026-10-05 | 0001373604-26-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 06, 2026 vote | Form 8-K | 2026-06-05 | 0001193125-26-259527 | Item 5.07 · say-on-pay result. As reported: 70.25% (votes for as printed: 7,548,774). Filing ↗ |
| 48 | Section 06, 2025 vote | Form 8-K | 2025-06-03 | 0000950170-25-081009 | Item 5.07 · say-on-pay result. As reported: 97.54% (votes for as printed: 13,574,133). Filing ↗ |
| 49 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 50 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 51 | Section 09b board cost (computed) | Computed | — | — | Cash 415,000 + equity 1,239,920 + all other 0 = 1,654,920, summed across the director compensation table rows.machine: formula: Σ = 1,654,920 |
| 52 | PROCEPT BioRobotics Corporation, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001588978-26-000017 | CEO total compensation as printed in PROCEPT BioRobotics Corporation's own proxy. As printed: 16,783,853. Filing ↗machine: r2 · c48 · span 520911–520921 |
| 53 | Nevro Corp., Section 10b CEO total | DEF 14A | 2024-04-12 | 0000950170-24-044100 | CEO total compensation as printed in Nevro Corp.'s own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993 |
| 54 | Adaptive Biotechnologies Corporation, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177409 | CEO total compensation as printed in Adaptive Biotechnologies Corporation's own proxy. As printed: 9,081,690. Filing ↗machine: span 818708–818717 |
| 55 | SI-BONE, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001459839-26-000049 | CEO total compensation as printed in SI-BONE, Inc.'s own proxy. As printed: 7,453,235. Filing ↗machine: r3 · c18 · span 626969–626978 |
| 56 | CareDx, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001217234-26-000028 | CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661 |
| 57 | Butterfly Network, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017118 | CEO total compensation as printed in Butterfly Network, Inc.'s own proxy. As printed: 6,382,814. Filing ↗machine: r2 · c22 · span 387435–387444 |
| 58 | AngioDynamics, Inc., Section 10b CEO total | DEF 14A | 2026-10-08 | 0001140361-26-039022 | CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. Filing ↗machine: r2 · c27 · span 739870–739879 |
| 59 | Treace Medical Concepts, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001630627-26-000005 | CEO total compensation as printed in Treace Medical Concepts, Inc.'s own proxy. As printed: 5,405,190. Filing ↗machine: t81 · r4 · c16 · span 1034150–1034159 |
| 60 | Accuray Incorporated, Section 10b CEO total | DEF 14A | 2026-10-16 | 0001140361-26-039918 | CEO total compensation as printed in Accuray Incorporated's own proxy. As printed: 5,114,466. Filing ↗machine: r2 · c24 · span 597587–597596 |
| 61 | Neuronetics, Inc., Section 10b CEO total | 10-K | 2026-04-09 | 0001140361-26-013997 | CEO total compensation as printed in Neuronetics, Inc.'s own proxy. As printed: 4,365,064. Filing ↗machine: r2 · c24 · span 376175–376185 |
| 62 | Pacific Biosciences of California, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001299130-26-000064 | CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983 |
| 63 | Tactile Systems Technology, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001104659-26-034206 | CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. Filing ↗machine: r3 · c12 · span 865797–865806 |
| 64 | Outset Medical (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177150 | CEO total compensation as printed in Outset Medical's own proxy. As printed: 3,255,510. Filing ↗machine: r2 · c30 · span 1343364–1343373 |
| 65 | Paragon 28, Inc., Section 10b CEO total | DEF 14A | 2024-04-05 | 0001193125-24-088613 | CEO total compensation as printed in Paragon 28, Inc.'s own proxy. As printed: 3,232,420. Filing ↗machine: t193 · r2 · c31 · span 598805–598814 |
| 66 | Inogen, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001294133-26-000009 | CEO total compensation as printed in Inogen, Inc.'s own proxy. As printed: 2,613,804. Filing ↗machine: span 1140571–1140580 |
| 67 | NeuroPace, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001140361-26-015894 | CEO total compensation as printed in NeuroPace, Inc.'s own proxy. As printed: 2,408,566. Filing ↗machine: r2 · c21 · span 339764–339773 |
| 68 | Sight Sciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016138 | CEO total compensation as printed in Sight Sciences, Inc.'s own proxy. As printed: 2,005,608. Filing ↗machine: r2 · c18 · span 798195–798204 |
| 69 | Section 10a, Pacific Biosciences of California, Inc. reciprocity | DEF 14A | — | 0001299130-26-000064 | Pacific Biosciences of California, Inc.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 70 | Section 10a, PROCEPT BioRobotics Corporation reciprocity | DEF 14A | — | 0001588978-26-000017 | PROCEPT BioRobotics Corporation's most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 71 | Section 10a, Accuray Incorporated reciprocity | DEF 14A | — | 0001140361-26-039918 | Accuray Incorporated's most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 72 | Section 10a, Adaptive Biotechnologies Corporation reciprocity | DEF 14A | — | 0001193125-26-177409 | Adaptive Biotechnologies Corporation's most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 73 | Section 10a, AngioDynamics, Inc. reciprocity | DEF 14A | — | 0001140361-26-039022 | AngioDynamics, Inc.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 74 | Section 10a, CareDx, Inc. reciprocity | DEF 14A | — | 0001217234-26-000028 | CareDx, Inc.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 75 | Section 10a, Inogen, Inc. reciprocity | DEF 14A | — | 0001294133-26-000009 | Inogen, Inc.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 76 | Section 10a, SI-BONE, Inc. reciprocity | DEF 14A | — | 0001459839-26-000049 | SI-BONE, Inc.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 77 | Section 10a, Sight Sciences, Inc. reciprocity | DEF 14A | — | 0001140361-26-016138 | Sight Sciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 78 | Section 10a, Tactile Systems Technology, Inc. reciprocity | DEF 14A | — | 0001104659-26-034206 | Tactile Systems Technology, Inc. names Outset Medical in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 79 | Section 10a, Treace Medical Concepts, Inc. reciprocity | DEF 14A | — | 0001630627-26-000005 | Treace Medical Concepts, Inc.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 80 | Section 10a, Nevro Corp. reciprocity | DEF 14A | — | 0000950170-24-044100 | Nevro Corp.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
| 81 | Section 10a, Paragon 28, Inc. reciprocity | DEF 14A | — | 0001193125-24-088613 | Paragon 28, Inc.'s most recent proxy was read; its disclosed peer group does not include Outset Medical. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.